高血压治疗的依从性：联合治疗的潜力。
Compliance with the treatment of hypertension: the potential of combination therapy.
机构信息
Department of Cardiology, Cerrahpaşa Medical School, University of Istanbul, Istanbul, Turkey.
出版信息
J Clin Hypertens (Greenwich). 2010 Jan;12(1):40-6. doi: 10.1111/j.1751-7176.2009.00200.x.
Abstract
Patient adherence to antihypertensive medication is vital to ensure the successful treatment of hypertension. Low levels of adherence to and persistence with prescribed therapy are major factors leading to the current poor rates of blood pressure control among patients with hypertension. There are many reasons for nonadherence to therapy including patient-, physician-, and therapy-related factors. Poor tolerability has a detrimental effect on adherence, therefore reducing the apparent effectiveness of agents with dose-dependent side effects. Various effective combination therapies are recommended by current guidelines, eg, beta-blocker plus calcium channel blocker (CCB), angiotensin receptor blocker (ARB) plus thiazide diuretic, angiotensin-converting enzyme (ACE) inhibitor plus thiazide diuretic, CCB plus thiazide diuretic, ACE inhibitor plus CCB, and ARB plus CCB, and these have the potential to increase adherence to therapy by combining a favorable tolerability profile with once-daily dosing.
摘要
患者对抗高血压药物的依从性对于确保高血压的成功治疗至关重要。对规定治疗的依从性和持久性低是导致高血压患者目前血压控制率差的主要因素。不依从治疗有很多原因，包括患者、医生和治疗相关因素。药物耐受性差会对依从性产生不利影响，从而降低具有剂量依赖性副作用的药物的显效性。目前的指南推荐了各种有效的联合治疗方法，例如β受体阻滞剂加钙通道阻滞剂（CCB）、血管紧张素受体阻滞剂（ARB）加噻嗪类利尿剂、血管紧张素转换酶（ACE）抑制剂加噻嗪类利尿剂、CCB 加噻嗪类利尿剂、ACE 抑制剂加 CCB、ARB 加 CCB，这些方法有可能通过将良好的耐受性与每日一次的剂量结合起来，提高治疗的依从性。
相似文献
1
Compliance with the treatment of hypertension: the potential of combination therapy.
J Clin Hypertens (Greenwich). 2010 Jan;12(1):40-6. doi: 10.1111/j.1751-7176.2009.00200.x.
2
Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
Clin Drug Investig. 2010;30(9):625-41. doi: 10.2165/11538440-000000000-00000.
3
Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations.
Expert Opin Pharmacother. 2012 Feb;13(3):345-55. doi: 10.1517/14656566.2012.652086. Epub 2012 Jan 6.
4
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Hypertens Res. 2002 Nov;25(6):849-55. doi: 10.1291/hypres.25.849.
5
Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database.
Hypertens Res. 2019 Feb;42(2):249-256. doi: 10.1038/s41440-018-0127-0. Epub 2018 Nov 16.
6
Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
Curr Med Res Opin. 2008 Aug;24(8):2389-401. doi: 10.1185/03007990802262457. Epub 2008 Jul 9.
7
Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
Hypertens Res. 2011 Mar;34(3):331-5. doi: 10.1038/hr.2010.233. Epub 2010 Dec 2.
8
Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
J Cardiovasc Nurs. 2009 Sep-Oct;24(5):380-9. doi: 10.1097/JCN.0b013e3181aed18e.
9
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Vasc Health Risk Manag. 2012;8:371-80. doi: 10.2147/VHRM.S28359. Epub 2012 Jun 11.
引用本文的文献
1
Nutritional Discrepancies Among Inpatients and Outpatients Diagnosed with Hypertension.
Healthcare (Basel). 2024 Oct 24;12(21):2119. doi: 10.3390/healthcare12212119.
2
Dishing out the meds.
Br J Cardiol. 2024 Jan 16;31(1):001. doi: 10.5837/bjc.2024.001. eCollection 2024.
3
Combined management can decrease blood pressure: an investigation of health-seeking behaviors among hypertensive patients in urban communities in China.
BMC Cardiovasc Disord. 2021 May 25;21(1):256. doi: 10.1186/s12872-021-02073-8.
4
The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis.
J Clin Hypertens (Greenwich). 2018 May;20(5):902-907. doi: 10.1111/jch.13272. Epub 2018 Apr 27.
5
Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects.
Drug Des Devel Ther. 2018 Mar 14;12:545-553. doi: 10.2147/DDDT.S156492. eCollection 2018.
6
Larger Blood Pressure Reduction by Fixed-Dose Compared to Free Dose Combination Therapy of ACE Inhibitor and Calcium Antagonist in Hypertensive Patients.
Transl Med UniSa. 2017 Jul 1;16:17-23. eCollection 2017 Jan.
7
Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study.
Drug Des Devel Ther. 2016 Sep 20;10:3021-3028. doi: 10.2147/DDDT.S113891. eCollection 2016.
8
One year follow-up effect of renal sympathetic denervation in patients with resistant hypertension.
ARYA Atheroscler. 2016 Mar;12(2):109-13.
9
Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension.
Vasc Health Risk Manag. 2013;9:95-104. doi: 10.2147/VHRM.S40963. Epub 2013 Mar 16.
10
Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration.
High Blood Press Cardiovasc Prev. 2013 Mar;20(1):25-32. doi: 10.1007/s40292-013-0013-4. Epub 2013 May 9.
本文引用的文献
1
Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Clin Drug Investig. 2009;29(7):427-439. doi: 10.2165/00044011-200929070-00001.
2
Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Clin Drug Investig. 2009;29(1):11-25. doi: 10.2165/0044011-200929010-00002.
3
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.
4
Impact of telemonitoring at home on the management of elderly patients with congestive heart failure.
J Telemed Telecare. 2008;14(6):300-5. doi: 10.1258/jtt.2008.071213.
5
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
Clin Ther. 2008 Apr;30(4):587-604. doi: 10.1016/j.clinthera.2008.04.002.
6
Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.
BMJ. 2008 May 17;336(7653):1114-7. doi: 10.1136/bmj.39553.670231.25. Epub 2008 May 14.
7
Telmisartan, ramipril, or both in patients at high risk for vascular events.
N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.
8
Actively engaging patients in treatment decision making and monitoring as a strategy to improve hypertension outcomes in diabetes mellitus.
Circulation. 2008 Mar 18;117(11):1355-7. doi: 10.1161/CIRCULATIONAHA.108.764514.
9
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Clin Ther. 2007 Apr;29(4):563-80. doi: 10.1016/j.clinthera.2007.03.018.
10
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
J Hypertens. 2007 Jun;25(6):1105-87. doi: 10.1097/HJH.0b013e3281fc975a.
Zotero 插件